[ad_1]
[사진 = 연합뉴스]▶ Click here to enlarge
The US International Trade Commission (ITC) admitted Daewoong Pharmaceutical’s charges of stealing the Medytox strain and manufacturing process through a final ruling on the lawsuit for infringing trade secrets of botulinum strains (also known as Botox) on the 16th (local time), but the conflict between the two companies deepened. I am going. Medytox is in Daewoong Pharmaceutical’s position “We will proceed with the abolition of the botulinum toxin drug project” Nabota “, and Daewoong Pharmaceutical will” appeal “against all established charges.
On the 18th, the US law firm Medytox was convicted in the final judgment of the US International Trade Commission (ITC) on the 16th (local time) as “the suspicion of Daewoong Pharmaceutical ( hereinafter referred to as Daewoong) of strain theft and manufacturing technology. Daewoong’s illegal acts will be revealed in detail throughout the entire sentence. ”
According to Medytox, the ITC’s final decision was made through extensive evidence disclosure procedures, full genome sequencing, scientific verification by experts, and hearings for evidence hearings. For this reason, it is believed that the same conclusion can only be reached in domestic civil and criminal trials. Medytox plans to ban the use of stolen strains and technologies, rights of return, and abolish Daewoong Pharmaceutical’s botulinum toxin drug ‘Nabota’.
“The fact that Daewoong stole the Medytox strain and manufacturing process is clearly stated in the final judgment of the ITC,” said attorney in charge of Clearly Gatlip Steen & Hamilton, a US law firm representing the lawsuit of Medytox before the ITC. If the full text of the final judgment on the page is posted within 10 days (based on business days), you can see how Daewoong stole the Medytox strain and manufacturing process, and how Nabota (DWP-450) was developed using this method. “He said.
Medytox hopes to expedite domestic civil and criminal lawsuits based on Daewoong’s theft allegations specified in the full text of the ITC ruling. Medytox filed a civil lawsuit with the Seoul Central District Court in 2017, alleging that Daewoong had stolen Medytox’s botulinum strain and its trade secret manufacturing process, and has now proceeded to the seventh plea.
A Meditox official said: “There is already a situation where the data presented to the US ITC has been presented to the court” and “As a large amount of scientific evidence has been presented to prove the suspicion of theft Daewoong strain and manufacturing process technology, the same judgment as the ITC has been filed in internal civil matters. ” It’s going to come out. ”
Daewoong Pharmaceutical largely objects to Medytox’s claims. It is an obvious false claim. Daewoong Pharmaceutical insists that the ITC deemed the strain not a trade secret in the final trial and that it was “really winning.” Although the theft of the manufacturing process was admitted, the plan is to appeal this as well. It is said that there is no trade secret infringement as a proprietary patent manufacturing method has been secured. Even if the importation of Nabota into the US is temporarily banned, it has also announced that it will continue to expand its global business.
Medytox has claimed that Daewoong Pharmaceutical created Nabota by stealing its own botulinum strain. In January last year, he filed a lawsuit against the US ITC against Daewoong Pharmaceutical and its US partner Ebolus for infringing trade secrets, and on the 16th received a final judgment that read: “US imports from Navota are banned for 21 months.” This is the result of a notable relaxation in the July preliminary ruling, which read: “The 10-year import ban. Medytox plans to proceed with appeals and other proceedings against the ITC committee’s determination that the strain is not a trade secret.
[김시균 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
